Glenmark launches Covid-19 drug FabiFlu in India at Rs 103 per tablet
Glenmark launches Covid-19 drug FabiFlu in India at Rs 103 per tablet
The drug will be available as a 200 mg per tablet at a MRP of Rs 3,500 for a strip of 34 tablets, Sources from Glenmark Pharmaceuticals said.
The company on Saturday said it has launched antiviral drug Favipiravir, that is under the brand name FabiFlu, for the treatment of corona patients with mild to moderate corona at a price of around Rs 103 per tablet.
This drug will be available as a 200 MG tablet with a MRP Rs 3,500 for a strip of 34 tablets, Sources said.
Not to mention that, FabiFlu is the first oral favipiravir-approved medicine in India for the treatment of corona virus, it added.
It is a however a prescription-based medication, with recommended dose being around 1,800 mg twice daily on day one, which is followed by 800 mg twice daily to be taken up to day 14, the drug firm said.
Drug Capacity:
When asked about the drug manufacturing capacity of company , the pharmaceutical company said: “Considering a minimum of two strips per patient, Glenmark will be able to provide Fabiflu to approximately 82,500 patients in just 1 month. We will closely monitor the evolving situation and work to meet and meet the health needs of the country by basing the situation.
Manufacturing Plant:
The company is producing active pharmaceutical ingredients (APIs) for the product at its Ankleshwar plant, while manufacturing at its bed plant.
Availability of Corona Drug:
Glenmark said the drug would be available through both hospitals and retail channels. Asked if the company was looking for alliances with hospitals to supply the drug, he said: “Our effort right now is to prioritize manufacturing to ensure that Fabiflu is accessible to all patients who need it the wanted. Glenmark will certainly consider supporting private and public health facilities and arranging other suitable options as needed and over time ”.
The Mumbai-based firm obtained manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday. “This approval comes at a time when cases in India are spiraling as before, putting tremendous pressure on our healthcare system. “Said Glenn Saldanha, president and MD of Glenmark Pharmaceuticals. The company hopes the availability of effective treatments such as Fabiflu will help ease this pressure, and provide patients with much needed and timely medical options in India.
Future plans of Company:
Saldanha said Glenmark will work closely with the government and the medical community to make febiflu quickly available to patients around the country. Glenmark said the company has developed APIs and formulas for FabiFlu through its in-house research and development team. “We decided to start work on favipirvir, as it has proven in-vitro activity against the SARS CoV2 virus, the virus responsible for Corona.
Glenmark Pharmaceutical President India Formulation, Middle East and Africa Sujesh Vasudevan said in an online press conference, “The other thing is that we have a wide therapeutic safety margin for Covid-19 at the doses we have.” In addition, it is an oral product and is a major benefit, especially when the hospital infrastructure is under stress.
The drugmaker said that in view of the emergency of the Covid-19 outbreak in India, the manufacturing and marketing consent has been approved as part of an expedited approval process. The use of medication is responsible for the restricted use of approval, where every patient should have signed informed consent before beginning treatment.
Glenmark said Favipiravir may be used for patients with co-morbid, such as mild to moderate COVID-19 symptoms with diabetes and heart disease. It provides a rapid reduction in viral load within four days and provides rapid symptomatic and radiological improvement.
Favipirvir has shown improvement of up to 88 percent in mild to moderate COVID-19 cases. Favipirvir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. Last month, Glenmark also announced that it was conducting another clinical trial to evaluate the efficacy of two antiviral favivirivir and umifenovir as combination therapy in moderately hospitalized adult COVID-19 patients in India.
India saw another record spike in 14,516 new COVID-19 cases in a single day on Saturday, bringing the tally to 3,95,048, while according to Union Healthcare data, the number of deaths with 375 new deaths is 12,948. Has gone.